Fig. 2

THOR methylation status in breast carcinoma. A Pyrosequencing analysis reveals that THOR methylation levels are significantly higher in normal adjacent tissue (P < 0.0001) and malignant breast tissue (P < 0.0001) when compared to healthy benign tissue in discovery cohort, being also increased in the malignant tissue when compared to its corresponding normal (P = 0.0119, discovery cohort). B Pyrosequencing analysis reveals that THOR methylation levels are significantly higher in malignant breast tissue when compared to healthy benign tissue (P < 0.0001) in the validation cohort. C THOR methylation is significantly higher between any disease stage and benign tissue (P < 0.0001). D THOR methylation levels according to hormone receptors and HER2 status in comparison with benign tissue (P < 0.0001). Statistical differences were assessed using the two-tailed Mann–Whitney U test (A and B) and the Kruskal–Wallis test (C and D). Statistical significance was considered as follows, *P < 0.05, **P < 0.01 and ***P < 0.001